2005-07-14-世界卫生组织-Weekly_epidemiological_record,_2005,_vol._80,_28_full_issue_8页_151kb

Weekly Epidemiological Record Issue #28 - July 15, 2005

Outbreak News:

1. Cholera, Senegal:
   • Update (News 241): Senegal's Ministry of Health reported 469 cases, down slightly from previous weeks, with 4 deaths (CFR 0.9%), using existing anti-HEJE vaccines.
   • Impact: F. marked increase in Mbour District (52 cases vs.14 prev. week). New affected: Bakel District.

Le Point Sur Les Epidémies:

1. Choléra, Sénégal - Mise à Jour (News 241): Ministry supports control measures via health education & environment. Below-representslide case reduction.
2. Poliomyélite, Indonésie - Mise à Jour (News 242): 122 total cases via Java West province. IP New case reduction observed. Large vaccination drive (26 June) vaccinated 78k children. Future campaigns planned for other regions.
3. Comité Consultatif Mondial de la Sécurité Vaccinale (GACVS) (News 242): June 9-10 Geneva meetings covering:
   • Vaccine Safety: Reviewed JE (Mouse Brain-derived + SA-14-14-2) efficacy/safety, recommendations unchanged w.approved new vaccines.
   • Thiomersal: Studies ongoing. Assessments standard policies based on current data.
   • Hexavalent/Vacins: No causal link established w.SUD, recommend sequential studies.
   • SSPE/Rougeole: Surveillance ongoing, recommends updating review.
   • Regulatory Capacity: Building programs globally, targeting 68+ national systems w.Support via networks/twins.
4. Missed Opportunities/Revaccination: Incidence covered by January 2004 survey. Revaccination campaign recommendations vary slightly w.International models.
5. Other Updates: France assists analyses. Turkey ratification on operations, which allows large-scale and private entities to carry out operations.

Key Actions/Discussions

• Senegal reduced cholera after introducing vaccines.
• Indonesia continues polio vaccination campaign post-revision.
• GACVS prioritizes evaluating newer vaccines for existing conditions.
• Collaboration emphasized for vaccine safety for efficient market access.
• Efforts continue monitoring adverse event reporting systems.